• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

BBB研究:强化降压治疗对“血压控制良好”的高血压患者的血压水平、副作用、发病率和死亡率的影响。更好地治疗血压。

The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive patients. Behandla Blodtryck Bättre.

作者信息

Hannson L

出版信息

Blood Press. 1994 Jul;3(4):248-54. doi: 10.3109/08037059409102265.

DOI:10.3109/08037059409102265
PMID:7994450
Abstract

The BBB study (Swedish for Behandla Blodtryck Bättre or Treat Blood Pressure Better) was a multicenter trial designed to investigate three aspects of antihypertensive treatment: i) Is it possible to lower the diastolic blood pressure further in "well-treated" hypertensive patients through intensified therapy? ii) Can this aim be fulfilled without increasing the incidence or severity of side-effects? iii) If i) and ii) can be answered in the affirmative, will the further reduction in diastolic blood pressure be associated with a further reduction in hypertension-associated mortality and morbidity? Altogether 2127 hypertensive men and women with an average age of 59.8 years (46-71) were recruited at 142 primary health care centers in Sweden. Approximately 10,000 patient-years were accumulated. All patients had treated essential hypertension and all had diastolic blood pressures in the range 90-100 mmHg on three consecutive visits before entering the study. The patients were randomized to either intensified treatment aiming at a blood pressure < or = 80 mmHg diastolic (group A) or to unchanged therapy (group B). A difference between group A and group B in diastolic blood pressure of 7-7.5 mmHg was achieved for > 4 years. Adverse effects were studied in detail in 100 randomly selected patients from each group using a special questionnaire and a visual analogue scale. The adverse effect score fell significantly in group A but remained unchanged in group B. Regarding cardiovascular morbidity and mortality there were no significant differences between groups A and B, the total number of strokes and myocardial infarcts being 28 in group A and 29 in group B.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

BBB研究(瑞典语“Behandla Blodtryck Bättre”,意为“更好地治疗血压”)是一项多中心试验,旨在研究降压治疗的三个方面:i)通过强化治疗,能否使“治疗良好”的高血压患者的舒张压进一步降低?ii)能否在不增加副作用发生率或严重程度的情况下实现这一目标?iii)如果对i)和ii)的回答是肯定的,舒张压的进一步降低是否会导致高血压相关死亡率和发病率的进一步降低?在瑞典的142个初级卫生保健中心共招募了2127名平均年龄为59.8岁(46 - 71岁)的高血压男性和女性。累计约10000患者年。所有患者均患有原发性高血压,且在进入研究前连续三次就诊时舒张压均在90 - 100 mmHg范围内。患者被随机分为强化治疗组(目标舒张压≤80 mmHg,A组)或维持原治疗组(B组)。4年多来,A组和B组的舒张压差值达到7 - 7.5 mmHg。使用特殊问卷和视觉模拟量表对每组随机抽取的100名患者进行了详细的副作用研究。A组的副作用评分显著下降,而B组保持不变。关于心血管发病率和死亡率,A组和B组之间无显著差异,A组中风和心肌梗死总数为28例,B组为29例。(摘要截选至250字)

相似文献

1
The BBB Study: the effect of intensified antihypertensive treatment on the level of blood pressure, side-effects, morbidity and mortality in "well-treated" hypertensive patients. Behandla Blodtryck Bättre.BBB研究:强化降压治疗对“血压控制良好”的高血压患者的血压水平、副作用、发病率和死亡率的影响。更好地治疗血压。
Blood Press. 1994 Jul;3(4):248-54. doi: 10.3109/08037059409102265.
2
The BBB study: a prospective randomized study of intensified antihypertensive treatment. The BBB study group.
J Hypertens. 1988 Sep;6(9):693-7. doi: 10.1097/00004872-198809000-00002.
3
The Hypertension Optimal Treatment (HOT) Study: 12-month data on blood pressure and tolerability. With special reference to age and gender.高血压最佳治疗(HOT)研究:关于血压和耐受性的12个月数据。特别提及年龄和性别。
Blood Press. 1995 Sep;4(5):313-9. doi: 10.3109/08037059509077613.
4
The Felodipine Event Reduction (FEVER) Study: a randomized long-term placebo-controlled trial in Chinese hypertensive patients.非洛地平降压疗效和安全性研究(FEVER):一项针对中国高血压患者的随机、长期、安慰剂对照试验。
J Hypertens. 2005 Dec;23(12):2157-72. doi: 10.1097/01.hjh.0000194120.42722.ac.
5
Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) trial of cardiovascular events in high-risk hypertensive patients: rationale, design, and methods.日本坎地沙坦抗高血压生存评估(CASE-J)试验:高危高血压患者心血管事件的基本原理、设计与方法
Hypertens Res. 2003 Dec;26(12):979-90. doi: 10.1291/hypres.26.979.
6
The Hypertension Optimal Treatment study and the importance of lowering blood pressure.高血压最佳治疗研究及降低血压的重要性。
J Hypertens Suppl. 1999 Feb;17(1):S9-13.
7
The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.老年人认知与预后研究(SCOPE):一项随机双盲干预试验的主要结果
J Hypertens. 2003 May;21(5):875-86. doi: 10.1097/00004872-200305000-00011.
8
Antihypertensive control and new-onset atrial fibrillation: Results from the Swedish Primary Care Cardiovascular Database (SPCCD).抗高血压治疗控制与新发心房颤动:来自瑞典初级保健心血管数据库(SPCCD)的结果。
Eur J Prev Cardiol. 2017 Jul;24(11):1206-1211. doi: 10.1177/2047487317708266. Epub 2017 May 4.
9
Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VALUE trial.VALUE 试验中高血压患者不同治疗时血压的心血管结局。
Eur Heart J. 2016 Mar 21;37(12):955-64. doi: 10.1093/eurheartj/ehv633. Epub 2015 Nov 20.
10
Major antihypertensive intervention trials conducted outside the United States.
Am J Hypertens. 1996 Aug;9(8):45S-49S. doi: 10.1016/0895-7061(96)00182-3.

引用本文的文献

1
Systematic Review of the Effectiveness of Intensive Antihypertensive Treatment Goals: Brazilian Society of Cardiology (SBC) Recommendation.强化降压治疗目标有效性的系统评价:巴西心脏病学会(SBC)建议
Arq Bras Cardiol. 2025 Mar;122(3):e20240761. doi: 10.36660/abc.20240761.
2
Blood pressure targets for hypertension in people with chronic renal disease.高血压合并慢性肾脏病患者的血压目标。
Cochrane Database Syst Rev. 2024 Oct 15;10(10):CD008564. doi: 10.1002/14651858.CD008564.pub3.
3
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.
高血压和心血管疾病患者的血压治疗目标。
Cochrane Database Syst Rev. 2022 Nov 18;11(11):CD010315. doi: 10.1002/14651858.CD010315.pub5.
4
Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study.收缩压升高对缺血性心脏病的影响:证据负担研究。
Nat Med. 2022 Oct;28(10):2056-2065. doi: 10.1038/s41591-022-01974-1. Epub 2022 Oct 10.
5
Blood pressure control in older adults with hypertension: A systematic review with meta-analysis and meta-regression.老年高血压患者的血压控制:一项包含荟萃分析和荟萃回归的系统评价
Int J Cardiol Hypertens. 2020 Jul 7;6:100040. doi: 10.1016/j.ijchy.2020.100040. eCollection 2020 Sep.
6
Blood pressure targets in adults with hypertension.高血压成人的血压目标。
Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. doi: 10.1002/14651858.CD004349.pub3.
7
Blood pressure targets for the treatment of people with hypertension and cardiovascular disease.高血压和心血管疾病患者治疗的血压目标
Cochrane Database Syst Rev. 2020 Sep 9;9(9):CD010315. doi: 10.1002/14651858.CD010315.pub4.
8
Low on-treatment diastolic blood pressure and cardiovascular outcome: A post-hoc analysis using NHLBI SPRINT Research Materials.治疗后舒张压低与心血管结局:利用 NHLBI SPRINT 研究资料的事后分析。
Sci Rep. 2019 Sep 10;9(1):13070. doi: 10.1038/s41598-019-49557-4.
9
Balance of benefits and harms of different blood pressure targets in people with multiple chronic conditions: a quantitative benefit-harm assessment.患有多种慢性病的人群中,不同血压目标的获益与危害平衡:一项定量获益-危害评估。
BMJ Open. 2019 Aug 30;9(8):e028438. doi: 10.1136/bmjopen-2018-028438.
10
Efficacy and toxicity of antihypertensive pharmacotherapy relative to effective dose 50.降压药物治疗的疗效和毒性与有效剂量 50 相关。
Br J Clin Pharmacol. 2019 Oct;85(10):2218-2227. doi: 10.1111/bcp.14033. Epub 2019 Aug 19.